Phathom Pharmaceuticals Inc
NASDAQ:PHAT

Watchlist Manager
Phathom Pharmaceuticals Inc Logo
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Watchlist
Price: 7.5 USD -1.45% Market Closed
Market Cap: 512.9m USD
Have any thoughts about
Phathom Pharmaceuticals Inc?
Write Note

Phathom Pharmaceuticals Inc
Investor Relations

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 77 full-time employees. The company went IPO on 2019-10-25. The Company’s pipeline product candidate, vonoprazan is an oral small molecule potassium-competitive acid blocker (P-CAB). P-CABs are a class of medicines that block acid secretion in the stomach. Vonoprazan has an anti-secretory effect and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease (GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.

Show more

Earnings Calls

Show Transcript
Previous
Next
Loading

Management

Ms. Terrie J. Curran
President, CEO & Director
No Bio Available
Mr. David A. Socks
Co-Founder & Director
No Bio Available
Dr. Azmi Nabulsi M.D., M.P.H.
Co-Founder & COO
No Bio Available
Ms. Molly Henderson CPA, MBA
Chief Financial & Business Officer
No Bio Available
Dr. Aditya Kohli Ph.D.
Co-Founder
No Bio Available
Mr. Paul Cocja
Chief People Officer
No Bio Available
Mr. Tom Harris
Chief Development Sciences Officer
No Bio Available
Dr. Eckhard Leifke M.D., Ph.D.
Chief Medical Officer
No Bio Available
Mr. Martin J. Gilligan
Chief Commercial Officer
No Bio Available

Contacts

Address
NEW JERSEY
Florham Park
100 Campus Drive,, Suite 102
Contacts